Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer

The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2025-01, Vol.156 (2), p.456-466
Main Authors: van de Weerd, Simone, Torang, Arezo, van den Berg, Inge, Lammers, Veerle, van den Bergh, Saskia, Brouwer, Nelleke, Nagtegaal, Iris D, Koopman, Miriam, Vink, Geraldine R, van der Baan, Frederieke H, van Krieken, Han, Koster, Jan, Ijzermans, Jan N, Roodhart, Jeanine M L, Medema, Jan Paul
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - genetics
Chemotherapy
Chemotherapy, Adjuvant - methods
Cohort analysis
Colon cancer
Colonic Neoplasms - classification
Colonic Neoplasms - drug therapy
Colonic Neoplasms - genetics
Colonic Neoplasms - mortality
Colonic Neoplasms - pathology
Colorectal cancer
Disease-Free Survival
Female
Humans
Male
Medical prognosis
Middle Aged
Multivariate analysis
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Patients
Prognosis
RESEARCH ARTICLE
Survival
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p 
ISSN:0020-7136
1097-0215
1097-0215
DOI:10.1002/ijc.35120